AbbVie ABBV remains a dominant force in the immunology segment, from where it generates nearly half of its top line. This ...

In June 2026, Merck reported positive Phase 3 results for its anti-TL1A antibody tulisokibart in moderately to severely active ulcerative colitis, alongside recent US FDA approvals expanding ...

For people living with immune-mediated inflammatory diseases (IMIDs), symptoms can become part of daily life in ways that are often invisible to others. These diseases, which include conditions like ...

Immunodeficient and humanized mouse models are driving innovation in oncology and immunology by enabling more predictive and ...

Shares of AbbVie ABBV rose more than 6% on Monday after the company announced that it entered into a definitive agreement to acquire clinical-stage biotech Apogee Therapeutics APGE for $135.11 per ...

Johns Hopkins University has established a Planning Committee for Immunology, a first step toward creating a new interdivisional entity to advance research in the field. Immunology is a branch of ...

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

Xencor is shifting from licensing optionality toward a broader portfolio of in-house assets across oncology and immunology.

The multi-billion-dollar bid could further cement AbbVie’s leading position in the immunology space as competition heats up.

Successful reproduction presents a fundamental evolutionary paradox: the immune system must tolerate genetically foreign sperm and embryos while maintaining ...

The division's Allergy and Immunology Clinic is known for its drug and food allergy testing; physicians utilize allergy shots and new oral immunotherapies to create tailored, effective treatment plans ...